Aurora IPF Phase 2 Study

AURORA – a Phase 2 IPF study of CAL101

The AURORA study is a randomized double-blind clinical trial to evaluate the efficacy and safety of CAL101 in patients with Idiopathic Pulmonary Fibrosis (IPF). The goal of this clinical trial is to learn if the investigational drug CAL101 can help reduce further decline in lung function in adults with IPF.

Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC).

Participants will be randomly assigned to a study group that will receive monthly IV infusions of either the study medication CAL101 or placebo about for 6 months.  60% of participants will receive the study medication CAL101 and 40% of participants will receive placebo.  Participants will be allowed to stay on their current treatments during the course of this trial.

For more information about the trial, please see link here: https://www.aurora-study.com/

Additional information can be found at clinicaltrials.gov NCT06736990